Although ROS1 is an independent receptor tyrosine kinase, several (though not all) targeted therapies designed for the treatment of ALK-positive metastatic NSCLC have also been recommended for use in the treatment of ROS1-positive metastatic diseases, like ceritinib, crizotinib, and lorlatinib309 with the median PFS ranged from 15.9 to 20 months across multiple trials. The gene discussed is ROS1; the disease is metastatic neoplasm.